Sarepta Therapeutics | SRPT - Current Liabilities


Sarepta Therapeutics reported $499.16M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Capricor Therapeutics USD 33.64M 2.2M Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Moderna USD 2.4B 408M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026